Two-Port Vitrectomy-free Subretinal Gene Therapy for Bietti Crystalline Dystrophy

The authors aimed to evaluate the safety and feasibility of a modified two-port, vitrectomy-free subretinal injection technique for gene therapy in patients with Bietti crystalline dystrophy. The study found that the procedure was completed without complications, with a significant proportion of patients experiencing improved visual acuity over a follow-up period of up to two years, suggesting that this approach may be a promising alternative to traditional methods. However, the authors note that further comparative studies with longer follow-up are needed to confirm these preliminary findings.